Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen
Benzinga Newsdesk 15 hours ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Benefits of continuous lecanemab treatment in early Alzheimer’s disease accrue over timeLecanemab reduced the relative risk of progression to the next stage of disease by 36% vs. ADNI62% of patients with low tau showed
- Benefits of continuous lecanemab treatment in early Alzheimer’s disease accrue over time
- Lecanemab reduced the relative risk of progression to the next stage of disease by 36% vs. ADNI
- 62% of patients with low tau showed improvement in cognitive function and activities of daily living (CDR-SB) at five years
